A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Clinical trial NCT05368285 · COMPLETED

Trial details

NCT number: NCT05368285
Sponsor: Celldex Therapeutics
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Spontaneous Urticaria

Start date: 2022-05-19
Primary completion: 2023-09-28
Enrollment: 208

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.